C-peptide (CP),
INTRODUCTION
The C-peptide (CP) is cleaved from proinsulin, stored in secretory granules, and eventually released into the bloodstream in amounts equimolar with those of insulin (Steiner et al., 1967) . During the past decade, numerous studies have demonstrated that CP, although not influencing blood sugar control , might play a role in a broad range of molecular and physiological activities, indicating that it is a hormonally active peptide. CP replacement in insulin dependent diabetes mellitus (IDDM, type 1 diabetes) patients and animal models of type 1 diabetes was accompanied by augmented blood flow in several tissues (Ido et al., 1997; Johansson et al., 2003) , diminished glomerular hyper *Corresponding author. E-mail: bioprocessor@yahoo.cn. or 19891996@sina.com. Tel/Fax: 0086 0510 85918119. filtration, reduction of urinary albumin excretion (Samnegard et al., 2004) and prevention of glomerular hypertrophy and mesangial matrix expansion (Samnegard et al., 2005) . Nociceptive sensory neuropathy (Kamiya et al., 2004) , nodal and paranodal degeneration , cognitive dysfunction and hippocampal apoptosis (Sima and Li, 2005) can likewise be prevented by CP administration. Moreover, CP may have beneficial effects on cavernosal smooth muscle relaxation and reduce the risk of infection in diabetes mellitus (Langer et al., 2002) . The biological half-life of CP in the plasma can last only about 20 min in rats by subcutaneous injection. It is possible to obtain more stable forms of a protein using gene fusion technology which can be used to express the target protein fused with human serum albumin (HSA). Fusion proteins with HSA can have long circulating life of albumin also with their biological and therapeutic properties (Giam et at., 2002). Many researchers have pursued insulin with longer biological half-time (Duttaroy et al., 2005) .
Here, a new fusion protein including proinsulin CP and HSA was constructed and expressed in Pichia pastoris, aiming to prolong the biological half-time of the protein and maintain CP bioactivity simultaneously.
MATERIALS AND METHODS

Strains, plasmids and regents
The Escherichia coli DH5α and E. coli XL-1 BLUE, used as the host for cloning the HSA cDNA, CP cDNA and HSA-CP cDNA were kindly provided by Prof. Li from Key laboratory of industrial Biotechnology, Ministry of education, Jiangnan University, China. The P. pastoris host strain GS115 and pPIC9K used for expressed were purchased from Invitrogen Co. (Beijing, China). The plasmid pBlue-HSA and T-CP were constructed in our laboratory.
The restriction endonucleases, DNA polymerase with highfidelity, and T4 ligase were purchased from Takara Co. (Dalian, China). Plasmid purification kit was purchased from Shanghai Sangon Co. (Shanghai, China). Human embryonic kidney 293 cell lines were purchased from Cell bank of Chinese academy of sciences (Shanghai, China). HSA polyclonal antibody was purchased from the Chengdu biological products, CP antibodies and CP standard were purchased from the Jingmei Co.(Nanjing, China).
Construction of fusion gene human serum albumin-CP (HSA-CP)
The CP gene was cloned from plasmid T-CP by polymerase chain reaction (PCR). The two PCR primers were designed as follows: Pr1 (5' GAAACCCTAGGCTTAGAAGCTGAGGACTTGCAAGTTGGTC 3') with Saul I site (underline) and Pr2 (5' GTTGCGGCCGCTTATTGAAGAGAACCTTCCAAAGCCA 3') with Not I site (underline). The PCR product was purified with gel extraction and digested with Saul I and Not I, and then it was cloned into the plasmid pBlue-HAS at restriction sites Saul I and Not I. The recombinant plasmid pBlue-HSA-CP was transformed into E. coli XL-1 BLUE and selected on lysogeny broth (LB) agar plates with 100 µg/ml ampicillin. The insertion was confirmed by restriction analysis and sequenced by Shanghai Sangon Co.
Construction of expression vector pPIC9K/ human serum albumin-CP (HSA-CP)
The plasmid pBlue-HSA-CP was digested with EcoR I and Not I, and then the insert was ligated to corresponding site of the expression vector pPIC9K. The constructed plasmid pPIC9K/ HSA-CP was transformed into E. coil DH5α strain and selected on LB agar plates with 100 µg/ml ampicillin. The expression plasmid pPIC9K/ HSA-CP was confirmed by both EcoR I and Not I digestion, and sent to Shanghai Sangon Co., for sequencing.
Transformation and selection of recombinant P. pastoris with high expression capacity of fusion protein
The resulting recombinant expression vector pPIC9K/ HSA-CP was digested with Saul I. Based on the procedure described in the operation manual of Pichia expression, the digested product was Yang et al. 16059 transformed into the P. pastoris GS115 under the condition of 40 µF, 150 Ω and 1.5 kV, which was spread on MD agar plates (1 mol/l sorbitol, 1.34% YNB, 0.004% histidine, 4×10 -5 % biotin, in w/v, pH 7.0) with 4.0 mg/ml G418 and incubated 48-72 h at 30°C.
The colonies were inoculated into flask containing 100 ml of BMGY medium (100 mM potassium phosphate, pH 6.0, 1.34% YNB, 4 ×10 -5 % biotin, 2% peptone, 1% yeast extract and 2% glycerol, w/v) and incubated under constant shaking at 30°C until A600 =20-30. The cells were collected by centrifugation (8000 rpm, 10 min). The cell pellet was re-suspended in 25 ml BMMY medium (BMGY with 2.0% methanol instead of glycerol) and the culture broth was transferred into a 250 ml flask. The cultures were incubated under constant shaking at 30°C for 72 h, with an additional 0.5 ml methanol every 24 h. The culture was harvested by centrifugation and the supernatant was collected. The concentration of the recombinant HSA-CP was measured by the kit of trace urinary albumin (MinDian Co., Shanghai). The clone with highest secreting level was selected based upon the concentration of HSA.
Purification of human serum albumin-CP (HSA-CP) from P. pastoris culture supernatant
The culture method of P. pastoris GS115 is the same as described in the operation manual of Pichia expression. After 72 h, the supernatant was harvested by centrifugation (8000 rpm, 15 min) and concentrated to 50 times by ultra filtration. The concentrated supernatant was loaded into a 2.6×15 cm Q-Sepharose fast flow column pre-equilibrated with buffer A (20 mM PB, pH 6.0). The column was washed with buffer A and the protein was eluted with a linear gradient from 0 to 1.0 M NaCl in 20 mM PB, at pH 6.0. The eluted protein was analyzed on 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE). The fractions containing HSA-CP were further concentrated by PEG 20,000 and loaded into a 1.6×90 cm Superdex 75 size-exclusion column preequilibrated with buffer B [20 mM phosphate-buffered saline (PBS) and 2.5 mM ethylene diamine tetraacetic acid (EDTA), pH 7.2]. The resulting solutions containing the targeted protein were analyzed on 12% SDS-PAGE and the concentration of recombinant HSA-CP was determined by the kit of trace urinary albumin.
SDS-PAGE and Western blotting assays
Analysis was performed with 12% SDS-PAGE. For Western blotting, proteins in the gel were transferred onto nitrocellulose membranes, and stained with Ponceau S to confirm equivalent transfer of samples. Membranes were blocked overnight at 4°C with Tris buffered saline (TBS; 10 mM Tris-HCl, 150 mM NaCl, pH 7.5) containing 3% skimmed milk. Thereafter, the membranes were incubated overnight at 4°C with the anti-human CP rabbit monoclonal antibody and the anti-HSA rabbit monoclonal antibody at a dilution of 1:100. The membranes were washed three times (5 min each) with TBS-T (TBS with 0.05% Tween 20) and incubated for 2 h at 37°C with the goat anti-rabbit IgG (HRP) (at dilution of 1:5000). Immunoreactivity was detected with diaminobenzidine (DAB) as a chromogenic substrate.
Bioactivity of human serum albumin-CP (HSA-CP) in vivo and in vitro
The study included three groups of Zucker diabetic fatty (ZDF) rats: (1) HSA-CP, 250 nmol/kg, sc, once daily; ( 2) HSA-CP, 500 nmol/kg, sc, once daily; (3) non-treated diabetic group ( control group). After 12 weeks, ratio of kidney weight/body weight (KW/BW), glomerular volume [V(glom)], extracellular matrix area The stably transfected HEK293 cells were seeded (2000 cells/well) in sterile 96-well plates in 100 µl Dulbecco's modified eagle's medium (DMEM) with 10% fetal calf serum (FCS) and incubated for 24 h at 37°C. HSA-CP and CP (control group without CP and HSA-CP) were added at different final concentrations (0.3，1，3，10，15，30，50，100，300 nM) in 100 µl DMEM plus 10% FCS. After incubation for 48 hours at 37°C, the cells were fixed in 50% trichloroacetate (TCA). The fixed cells were stained with 100 µl 0.4% sulphorhodamine B (SRB) in 1% acetic acid. Finally, the SRB dye was dissolved in 10 mM unbuffered Tris base (pH 10.5) for 10 min and measured at A540 in a microplate reader. The experiments were repeated at least three times.
The biological half-time of human serum albumin-CP (HSA-CP) in vivo
HSA-CP (500 nmo/kgl) was injected subcutaneously in Wister rats to study the metabolism characteristics. The plasma drug concentration was determined by immunoradiometric assay (IRMA).
RESULTS AND DISCUSSION
Construction of expression vector pPIC9K/ human serum albumin-CP (HSA-CP)
To improve the expression of HSA-CP, the codon usage of the gene encoding for CP was optimized according to P. pastoris codon bias and reduced repetitive AT and GC content. The artificial CP gene was fused to the HSA cDNA in the same reading frame. The fused gene HSA-CP was inserted into expression vector pPIC9k to construct recombinant plasmid pPIC9K/HSA-CP. The expression plasmid pPIC9K/HSA-CP was confirmed by agarose electrophoresis and DNA sequencing (data was not shown).
Expression and purification of fusion protein human serum albumin-CP (HSA-CP)
The recombinant expression vector pPIC9K/HSA-CP was linearized with Sal I, and the digested product was transformed into P. pastoris GS115. The concentration of secreted recombinant HSA-CP reached a peak level of 145 mg/L at 72 h. The molecular weight of the protein was approximately 70 kDa as determined by SDS-PAGE (Figure 1 ). Western blotting analysis showed that the protein was recognized specifically by goat anti-CP antibody and goat anti-HSA antibody, indicating that the expressed heterogeneous protein was recombinant HSA-CP (Figure 2) .
The secreted HSA-CP obtained from the culture broth was first purified by ultra filtration and Q-sepharose fast flow chromatography with most of the HSA-CP tightly binding to the column. The purified protein solution was concentrated with PEG 20,000 and further purified with a Superdex 75 size exclusion column. HSA-CP purity eventually reached over 90%, as revealed by SDS-PAGE ( Figure 1) . As a result, 46 mg of pure HSA-CP protein was obtained out of 1 L of the culture supernatant and the purification yield of the protein reached 20.5%.
Bioactivity of human serum albumin-CP (HSA-CP) in vitro
The effect of HSA-CP and CP on in HEK293 cell growth was investigated by SRB assay and the results are shown in Figure 3 . With the concentration increasing from 0.3 to 300 nM/L, CP and HSA-CP had effects on HEK293 cell proliferation, as compared with the control (without CP and HSA-CP). The optimal addition concentrations of HSA-CP and CP were 15 nM/L and 3 nM/L, respectively.
The effects of human serum albumin-CP (HSA-CP) in the treatment of rats with diabetic nephropathy
In ZDF rats, 12 weeks recombinant HSA-CP treatment (250 and 500 nmol/kg, sc, once daily) prevented the accumulation of glomerular extracellular matrix, which leads to mesangial expansion and glomerular hypertrophy but there was no prevention effect on whole kidney hypertrophy (Table 1) .
The elimination half-life of human serum albumin-CP (HSA-CP) in rats
The pharmacokinetics of HSA-CP were investigated in Wister rats (n=6) by IRMA. After injection subcutaneously with 500 nmol/kg HSA-CP, C max was achieved at 601±201 ng/mL. The elimination half-life (t 1/2 ) was calculated to be 3.38±1.87 h. Production strategies for recombinant small peptides gave relatively low yields of the target peptide. In order to increase the amount of produced target peptide, one strategy is to synthesize a gene product with multiple copies of the target peptide (Li et al., 2003; Shen, 1984) and the other is gene fusion strategy. Proteins resulting from HSA gene fusions have the long circulating life of albumin while retaining their biological and therapeutic properties (Osborn et al., 2002; Sung et al., 2003) . In this study, a new fusion protein including one CP mutant and one human albumin was properly designed. The strain efficiently expressing the fusion protein was successfully constructed with P. pastoris used as the host. With the expression system, HSA-CP could reach a maximum level of 145 mg/L at 72 h fermentation. The purity of the fusion protein reach 95% after purification with ultra filtration and columns in order. The recombinant HSA-CP protein obtained could stimulate HEK293 cell proliferation in vitro. The therapy of HSA-CP can prevent the accumulation of glomerular extracellular matrix. In addition, the biological half-time of the HSA-CP was about 10-fold longer than that of CP.
